Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Wright

Showing results (121-130 of 155) with videos related to

Pageof 16
Sort By:
Clinical and Vaccine Immunology : CVI|April 12, 2013
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccinationMark Y Sangster, Jane Baer, Felix W Santiago, et al.
Pathogens & Immunity|June 27, 2024
Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2Ruth I Connor, Mrunal Sakharkar, C Garrett Rappazzo, et al.
Bulletin of the World Health Organization|January 15, 2009
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretroviralsMacarthur Charles, Francine Noel, Paul Leger, et al.
The Journal of Infectious Diseases|January 25, 2014
Intestinal immunity is a determinant of clearance of poliovirus after oral vaccinationPeter F Wright, Wendy Wieland-Alter, Natalia A Ilyushina, et al.
AIDS Research and Treatment|December 31, 2014
Adapting and Implementing a Community Program to Improve Retention in Care among Patients with HIV in Southern Haiti: "Group of 6"John A Naslund, Jodie Dionne-Odom, Cléonas Junior Destiné, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Journal of Infectious Diseases|October 16, 2008
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individualsAnn R Falsey, Edward E Walsh, Jose Capellan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2025
Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newbornsAudrey Godin, Elizabeth B Brickley, Ruth I Connor, et al.
BMJ Global Health|September 24, 2019
Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in SwedenElizabeth B Brickley, Ruth I Connor, Wendy F Wieland-Alter, et al.
Nature Communications|August 24, 2023
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populationsAndrew P Hederman, Harini Natarajan, Leo Heyndrickx, et al.
Pageof 16

Showing results (121-130 of 155) with videos related to

Sort By:
Pageof 16
Clinical and Vaccine Immunology : CVI|April 12, 2013
B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following 2009 H1N1 influenza virus vaccinationMark Y Sangster, Jane Baer, Felix W Santiago, et al.
Pathogens & Immunity|June 27, 2024
Characteristics and Functions of Infection-enhancing Antibodies to the N-terminal Domain of SARS-CoV-2Ruth I Connor, Mrunal Sakharkar, C Garrett Rappazzo, et al.
Bulletin of the World Health Organization|January 15, 2009
Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretroviralsMacarthur Charles, Francine Noel, Paul Leger, et al.
The Journal of Infectious Diseases|January 25, 2014
Intestinal immunity is a determinant of clearance of poliovirus after oral vaccinationPeter F Wright, Wendy Wieland-Alter, Natalia A Ilyushina, et al.
AIDS Research and Treatment|December 31, 2014
Adapting and Implementing a Community Program to Improve Retention in Care among Patients with HIV in Southern Haiti: "Group of 6"John A Naslund, Jodie Dionne-Odom, Cléonas Junior Destiné, et al.
The Lancet. Infectious Diseases|August 16, 2025
Safety and immunogenicity of novel live attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA: a first-in-human, observer-masked, multicentre, phase 1 randomised controlled trialLaina D Mercer, Arlene C Seña, E Ross Colgate, et al.
The Journal of Infectious Diseases|October 16, 2008
Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines--nonadjuvanted vaccine or vaccine adjuvanted with alum--given concomitantly with influenza vaccine to high-risk elderly individualsAnn R Falsey, Edward E Walsh, Jose Capellan, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 4, 2025
Intestinal mucosal immune responses to novel oral poliovirus vaccine type 2 in healthy newbornsAudrey Godin, Elizabeth B Brickley, Ruth I Connor, et al.
BMJ Global Health|September 24, 2019
Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in SwedenElizabeth B Brickley, Ruth I Connor, Wendy F Wieland-Alter, et al.
Nature Communications|August 24, 2023
SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populationsAndrew P Hederman, Harini Natarajan, Leo Heyndrickx, et al.
Pageof 16